Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer
Metadatos
Mostrar el registro completo del ítemAutor
Aroca Siendones, María I.; Moreno SanJuan, Sara; Puentes Pardo, José David; Verbeni, Michela; Arnedo Fernández, Francisco Javier; Escudero Feliú, Julia; García Costela, María; García Robles, Adelina; Carazo Gallego, Ángel; León, JosefaEditorial
MDPI
Materia
Colorectal cancer Core circadian clock Metachronous metastasis Local recurrence Overall survival Disease free-survival
Fecha
2021Referencia bibliográfica
Aroca-Siendones, M.I.; Moreno-SanJuan, S.; Puentes-Pardo, J.D.; Verbeni, M.; Arnedo, J.; Escudero-Feliu, J.; García-Costela, M.; García-Robles, A.; Carazo, Á.; León, J. Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer. Biomedicines 2021, 9, 967. https://doi.org/10.3390/ biomedicines9080967
Patrocinador
Instituto de Salud Carlos III- FEDER (PI18/01947) and MINECO grant (DPI2017-84439-R); FPU2019 fellowship (FPU19/02269) from the Ministerio de Ciencia, Innovación y Universidades (Spain).; Nicolás Monardes Program from the Andalusian Health Service (C-0033-2015)Resumen
Colorectal cancer (CRC) is one of the most common tumours in developed countries.
Although its incidence and mortality rates have decreased, its prognosis has not changed, and a high
percentage of patients with CRC develop relapse (metachronous metastasis, MM, or local recurrence,
LR) during their disease. The identification of these patients is very important for their correct
management, but the lack of prognostic markers makes it difficult. Given the connection between
circadian disruption and cancer development and progression, we aimed to analyse the prognostic
significance of core circadian proteins in CRC. We measured the expression of PER1-3, CRY1-2,
BMAL1 and NR1D2 in a cohort of CRC patients by immunohistochemistry (IHC) and analysed
their prognostic potential in this disease. A low expression of PER2 and BMAL1 was significantly
associated with metastasis at the moment of disease diagnosis, whereas a high expression of CRY1
appeared as an independent prognostic factor of MM development. A high expression of NR1D2
appeared as an independent prognostic factor of LR development after disease diagnosis. Moreover,
patients with a low expression of BMAL1 and a high expression of CRY1 showed lower OS and DFS
at five years. Although these markers need to be validated in larger and different ethnic cohorts, the
simplicity of IHC makes these proteins candidates for personalizing CRC treatment.